Akro ^Hubs

IPO: Jun 20, 2019. CIK: 0001744659. Website: akerotx.com. Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth ...